This protocol describes the use of flow cytometry to identify the changes in immune cell composition, cytokine profile, and chemokine profile in the pulmonary environment following transient middle cerebral artery occlusion, a murine model of ischemic stroke.
Immune cell expansion, activation, and trafficking to the lungs, which are controlled by the expression of multiple cytokines and chemokines, may be altered by severe brain injury. This is evidenced by the fact that pneumonia is a major cause of mortality in patients who have suffered from ischemic stroke. The goal of this protocol is to describe the use of multicolor flow cytometric analysis to identify 13 types of immune cells in the lungs of mice, including alveolar macrophages, interstitial macrophages, CD103+ or CD11b+ dendritic cells (DCs), plasmacytoid DCs, eosinophils, monocytes/monocyte-derived cells, neutrophils, lymphoid-derived T and B cells, NK cells, and NKT cells, following ischemic stroke induction by transient middle cerebral artery occlusion. Moreover, we describe the preparation of lung homogenates using a bead homogenization method, to determine the expression levels of 13 different cytokines or chemokines simultaneously by multiplex bead arrays coupled with flow cytometric analysis. This protocol can also be used to investigate the pulmonary immune response in other disease settings, such as infectious lung disease or allergic disease.
The lungs are a barrier organ, exposed to the external environment and, therefore, are constantly receiving immunological challenges such as pathogens and allergens1. The activation of lung-resident immune cells and the infiltration of immune cells from the periphery are required to clear pathogens from the pulmonary environment. Additionally, lung-resident immune cells maintain tolerance to commensal bacteria, suggesting that these cells play a role in pathogen clearance and maintaining homeostasis1. Alveolar and interstitial macrophages are among the lung-resident sentinel immune cells that sense pathogens via pattern recognition receptors and clear these pathogens by phagocytosis2. Lung-resident dendritic cells bridge the innate and adaptive immune response through antigen presentation3. In addition, activated local innate immune cells produce cytokines and chemokines that amplify the inflammatory response and stimulate the infiltration of immune cells such as monocytes, neutrophils, and lymphocytes into the lungs1. Ischemic stroke has been shown to modify systemic immunity and lead to increased susceptibility to pulmonary infection; however, few studies have evaluated the pulmonary compartment following ischemic stroke, though some studies have examined it during inflammatory conditions4,5,6,7,8,9. The goal of the methods described herein is to simultaneously determine lung pathology, immune cell composition, and the levels of cytokine and chemokine expression in the lungs to evaluate alterations to the pulmonary compartment and assess potential alterations to the pulmonary immune response following ischemic attack.
Described here is a protocol for obtaining single cell suspensions from the lungs of the mice to identify 13 types of immune cells. This protocol is based on tissue digestion with collagenase D without the need of an automated tissue dissociator. Additionally, we developed a protocol to prepare tissue homogenates that can be used to determine the expression levels of 13 different cytokines or chemokines using flow cytometry-based multiplex bead arrays. This protocol was successfully used to investigate the effects of ischemic stroke on pulmonary immunity and can be used in other disease models as well.
All protocols and procedures performed were approved by the Institutional Animal Care and Use Committee (IACUC) of West Virginia University. The mice were housed under specific-pathogen-free conditions in the vivarium at West Virginia University.
1. Preparation of solutions
2. Transient middle cerebral artery occlusion (tMCAO)
NOTE: Procedures for tMCAO via monofilament insertion to the middle cerebral artery were documented in detail previously10. In these experiments, 8- to 12-week-old male C57BL/6J mice, weighing 25-30 g, were used.
3. Harvesting the lung tissues
4. Homogenization of lung tissue for multiplex bead arrays using bead homogenizer
5. Lung tissue dissociation and single cell isolation
6. Flow cytometric analysis for the lung immune cell niche
7. Multiplex bead arrays for cytokine and chemokine detection
NOTE: Commercially available proinflammatory chemokine and inflammation multiplex panels (see Table of Materials) were used to determine the expression of chemokines and cytokines in the lungs following tMCAO induction according to manufacturer protocol, which has been described in detail13.
We recently reported that ischemic stroke induction in mice alters the immune cell composition of the lungs11. Specifically, transient cerebral ischemia increased percentages of alveolar macrophages, neutrophils, and CD11b+ DCs, while diminishing percentages of CD4+ T cells, CD8+ T cells, B cells, NK cells, and eosinophils in the pulmonary compartment. Moreover, cellular alteration corresponded to significantly diminished levels of multiple chemokines in the lungs. Described here is a method for the isolation and identification of different immune cell populations in the pulmonary compartment. Representative results shown here were from mice that had undergone tMCAO induction and a sham operation.
We identified 13 different populations of immune cells in the lungs (L1-L13) using 3 sets of antibody combinations with each set containing 5-7 antibodies (Figure 1). Dead cells were excluded using a LIVE/DEAD stain in each set. Antibodies and markers for distinguishing different immune cell types are listed in Table 1. Alveolar and interstitial macrophages, CD103+ DCs, CD11b+ DCs, and eosinophils were identified in Set 1 (Figure 1A,B). Proinflammatory monocytes and neutrophils were identified in Set 2 (Figure 1C). During inflammatory responses, monocytes migrate to the site of inflammation, where these cells differentiate into monocyte-derived antigen presenting cells (mo-APCs)14. Downregulation of Ly6C and CCR2 are characteristic of monocyte differentiation, which can be evaluated using Set 215. CD4+ T cells, CD8+ T cells, B cells, plasmacytoid DCs, NK cells, and NKT cells were identified using Set 3 (Figure 1D).
To determine the quality of our single cell isolation protocol, we compared the number of viable cells and CD45+ immune cells isolated using the manual method with the cells isolated using a commercially available tissue dissociator (see Table of Materials), which is often used to isolate cells from tissues16,17,18,19,20. In the latter protocol, lung lobes were transferred into a dissociator-specific tube (see Table of Materials) following injection of the dissociation buffer, and the tissue was digested using the 37C_m_LDK_1 program. The total number of viable cells, percentage of CD45+ cells, and the total number of CD45+ cells obtained were comparable between the two methods (Figure 2A-C). The percentage of cell death among CD45+ cells using both protocols was ~ 10% (Figure 2D). These results suggest that the protocol presented here allows cell recovery with high yield and quality without the aid of an automated tissue dissociator.
A commercially available multiplex assay coupled with flow cytometric analysis was used to determine the concentration of 13 chemokines using 25 µL of sample (Figure 3). Two different sizes of beads were first identified by FSC/SSC (Figure 3A). Each bead is coated with 6-7 primary antibodies, which could be distinguished by fluorescence intensity in the APC channel (Figure 3B). The level of chemokines in the sample is proportional to the fluorescence intensity in the PE channel, which could be determined by MFI (Figure 3C). By comparing the MFI value of each chemokine with the standard curve constructed with known concentrations of chemokine, the concentration in the sample (per mg of tissue) can be determined.
Figure 1: Identification of 13 immune cell types from the lungs following tissue digestion with collagenase D following ischemic stroke. Lung tissues were excised 24 h following tMCAO or sham operation, immune cells in the lungs were analyzed by flow cytometry, defined by surface markers listed on Table 1. (A) In antibody set 1, CD45+ viable cells (*) were first gated on Siglec F and CD11b to identify the alveolar macrophages (L1), which expressed CD11c and MHC II, and eosinophils (L2), which did not express CD11c and MHC II. (B) Cells within the Siglec F- population (**) in A were then gated to determine the expression of CD103 and CD11b. CD103+ CD11b- (***). Cells were further gated to determine the expression of CD11c and MHC II. CD103+ DCs expressed both CD11c and MHC II (L3) but did not express CD64. The CD11b hi population (****) was further gated to determine the expression of CD64 and MHC II. CD11b+ DCs expressed MHC II but not CD64 (L4), whereas interstitial macrophages (L5) expressed both markers. (C) In antibody set 2, CD45+ viable cells in A were gated to determine the expression of CD11b and Ly6C. Ly6C hi cells (*) represented the undifferentiated monocytes that maintained a high level of CCR2 expression (L6, middle plot), whereas Ly6C low cells (**) contained a mixed population of differentiating monocytes that were Ly6G- (L6, right plot), and Ly6G+ neutrophils (L7). (D) In antibody set 3, CD45+ viable cells in A were gated to determine the expression of CD11c and B220 to identify B cells (L8) and plasmacytoid DCs (L9). The CD11c- and B220- population (*) was then gated to determine the expression of CD4 and CD8 to identify CD4+ T cells (L10) and CD8+ T cells (L11). The CD4- CD8- population (**) was further gated to determine the expression of NK1.1 and TCRb to identify NK cells (L12) and NKT cells (L13). Shown are representative plots from 12 C57BL/6J mice following tMCAO and sham operation. Parts of the figure have been reprinted from previously published literature11 with permission. Please click here to view a larger version of this figure.
Figure 2: Comparison between manual dissociation method and the use of tissue dissociator for isolating single cells from the lungs. (A-C) The total number of cells, the percentage of CD45+ cells, and the total number of CD45+ cells were compared. Shown are combined results from 3 independent experiments. NS: not statistically significant. (D) Representative plots to determine the percentage of dead CD45+ cells following isolation. Shown are representative plots from 3 independent experiments. Please click here to view a larger version of this figure.
Figure 3: Ischemic stroke suppresses the production of multiple chemokines in the lungs. (A-C) Representative plots showing the determination of the level of 13 chemokines in the lungs by multiplex bead array. (A) FSC/SSC gate was used to identify beads A and B with different size. (B) Primary antibodies coated on the beads could be distinguished by fluorescence intensity in the APC channel. (C) The level of chemokines in the sample was proportional to the fluorescence intensity in the PE channel. Shown are representative plots from 12 C57BL/6J mice following sham operation. (D) Lung tissues were homogenized 24 h following tMCAO or sham operatio. The level of 13 chemokines in the lungs of individual animals was determined by multiplex bead array. Data shown are combined results from three independent experiments with n = 11-12 animals per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. NS, not statistically different. Parts of the figure have been reprinted from previously published literature11 with permission. Please click here to view a larger version of this figure.
Antibody | Clone | Immune Cell Type | Population | Surface Marker Expression |
CD45-FITC | 30-F11 | Alveloar macrophages | L1 | CD45+ Siglec F+ CD11b- |
Siglec F-PE | E50-2440 | Eosinophils | L2 | CD45+ Siglec F+ CD11b+ |
CD11c-Percp/Cy5.5 | N418 | CD103+ DCs | L3 | CD45+ Siglec F- CD11b- CD103+ CD11c+ MHC II+ |
CD11b-PE/Cy7 | M1/70 | CD11b+ DCs | L4 | CD45+ Siglec F- CD11b hi CD103- CD64- MHC II+ |
CD64-APC | X54-5/7.1 | Interstitial macrophages | L5 | CD45+ Siglec F- CD11b hi CD103- CD64+ MHC II+ |
CD103-BV421 | 2E7 | |||
MHC II-BV510 | M5/114.15.2 | |||
Live/dead-APC/Cy7 | ||||
CD45-FITC | 30-F11 | Monocytes/moDCs | L8 | CD45+ CD11b hi Ly6C hi/int CCR2+/- Ly6G- |
Ly6C-PE | HK1.4 | Neutrophils | L9 | CD45+ CD11b hi Ly6C int CCR2- Ly6G+ |
CD11b-PE/Cy7 | M1/70 | |||
CCR2-BV421 | SA203G11 | |||
Ly6G-BV510 | 1A8 | |||
Live/dead-APC/Cy7 | ||||
CD45-FITC | 30-F11 | Plasmacytoid DCs | L6 | CD45+ B220+ CD11c+ |
CD8-PE | 53-6.7 | B cells | L7 | CD45+ B220+ CD11c- |
NK1.1-Percp/Cy5.5 | PK136 | CD4+ T cells | L10 | CD45+ B220- CD11c- CD4+ CD8- |
CD11c-PE/Cy7 | N418 | CD8+ T cells | L11 | CD45+ B220- CD11c- CD4- CD8+ |
APC-B220 | RA3-6B2 | NK cells | L12 | CD45+ B220- CD11c- CD4- CD8- NK1.1+ TCRb- |
CD4-BV421 | GK1.5 | NKT cells | L13 | CD45+ B220- CD11c- CD4- CD8- NK1.1+ TCRb+ |
TCRb-BV510 | H57-597 | |||
Live/dead-APC/Cy7 |
Table 1: Surface markers and antibody combinations for determining immune cells isolated from the lungs following tMCAO.
The protocols described here allow for the identification of lung immune cell types and the expression of chemokines or cytokines in the same mouse. If a histopathology study is desired, an individual lobe can be removed and fixed for that purpose prior to proceeding to the single cell isolation steps. One limitation of this method is that this approach may not be suitable in some disease settings if the change in the immune cell composition and the expression of chemokines and/or cytokines are anticipated to be unequally distributed between different lobes of the lungs. For example, some bacteria, such as Mycobacterium tuberculosis, show a predilection for infecting certain lobes of the lung21. In this case, a comparison between lobes may be required.
The concentration, incubation time, and temperature of the single cell isolation protocol from the lungs critically impact the recovery of the immune cells from the lungs. The quality of collagenase D is critical for obtaining optimal results and should be tested if a different source of collagenase D is used. Over-digestion of the tissues results in an increase of cell death; whereas, under-digestion of the tissues causes low yield of immune cells, especially macrophages and DCs.
We used 3 antibody combinations to determine 13 immune cell populations in the lungs, with each set containing 5-7 antibodies and a LIVE/DEAD stain. Antibodies in each set can be combined if the number of cells obtained from the samples is limited. However, one major issue that arises when the number of antibodies is increased is that the compensation of the fluorescence signal on the flow cytometer can be challenging, especially when distinguishing cells from myeloid linage under inflammatory conditions. Additional antibody cocktails can be used to identify other innate immune cells within the single-cell suspension, such as innate lymphoid cells and γδ T cells, that contribute to the immune response in the lungs22,23. Since one lobe of the lung is taken for the multiplex array, the exact number of each cell type in the lungs cannot be definitively determined and compared, and this constitutes a limitation of this method. To address this, a defined number of cells can be isolated from the lungs of sham and tMCAO-induced mice. In this case, the absolute number of each immune cell type can be accurately compared between the two groups. Additionally, this method does not allow the localization of the immune cells in the lung to be determined. This can be accomplished by performing immunohistochemistry on lung sections.
In conclusion, this protocol was used to investigate the effect of ischemic stroke in pulmonary immunity, but it can also be used to study other disease models, such as infection and allergies.
The authors have nothing to disclose.
This work was supported by NIH grant P20 GM109098 and the Innovation Award Program from Praespero to Edwin Wan. Flow Cytometry experiments were performed in the WVU Flow Cytometry & Single Cell Core Facility, which is supported by NIH grants S10 OD016165, U57 GM104942, P30 GM103488, and P20 GM103434.
B220-APC, clone RA3-6B2 | Biolegend | 103212 | 1:200 dilution |
Beadbug 3 position bead homogenizer | Benchmark Scientific | D1030 | Tissue homogenizer |
CCR2-BV421, clone SA203G11 | Biolegend | 150605 | 1:200 dilution |
CD103-BV421, clone 2E7 | Biolegend | 121422 | 1:200 dilution |
CD11b-PE/Cy7, clone M1/70 | Biolegend | 101216 | 1:400 dilution |
CD11c-PE/Cy7, clone N418 | Biolegend | 117318 | 1:200 dilution |
CD11c-Percp/Cy5.5, clone N418 | Biolegend | 117328 | 1:200 dilution |
CD4-BV421, clone GK1.5 | Biolegend | 100443 | 1:200 dilution |
CD45-FITC, clone 30-F11 | Biolegend | 103108 | 1:200 dilution |
CD64-APC, clone X54-5/7.1 | Biolegend | 139306 | 1:200 dilution |
CD8-PE, clone 53-6.7 | Biolegend | 100708 | 1:800 dilution |
Collagenase D | Sigma Aldrich | 11088882001 | Component in the dissociation buffer |
Conical screw cap tube | ThermoFisher | 02-681-344 | Tube for tissue homogenization |
DNase I | Sigma Aldrich | 10104159001 | Component in the dissociation buffer |
Fc block CD16/32 antibody | Biolegend | 101320 | 1:100 dilution |
genlteMACS dissociator | Miltenyi Biotec | 130-093-235 | Comparsion of lung digestion with or without mechanical dissociator |
gentleMACS C tubes | Miltenyi Biotec | 130-093-237 | Tube for tissue disscoiation with genlteMACS dissociator |
Halt protease and phosphatase inhibitor cocktial | ThermoFisher | 78442 | Component in the homogenization buffer |
Laser doppler monitor | Moor | MOORVMS-LDF | Blood flow monitoring during tMCAO |
LEGENDplex proinflammatory chemokine panel | Biolegend | 740451 | Multiplex bead array |
LIVE/DEAD fixable near-IR stain | ThermoFisher | L34976 | Use for dead cell exclusion during flow cytometric analysis |
Ly6C-PE, clone HK1.4 | Biolegend | 128008 | 1:800 dilution |
Ly6G-BV510, clone 1A8 | Biolegend | 127633 | 1:200 dilution |
MCAO suture L56 reusable 6-0 medium | Doccol | 602356PK10Re | tMCAO |
MHC II-BV510, clone M5/114.15.2 | Biolegend | 107636 | 1:800 dilution |
NK1.1-Percp/Cy5.5, clone PK136 | Biolegend | 108728 | 1:200 dilution |
Siglec F-PE, clone E50-2440 | BD Biosciences | 552126 | 1:200 dilution |
Silk suture thread, size 6/0 | Fine Science Tools | 18020-60 | tMCAO |
SomnoSuite anesthesia system | Kent Scientific | SS-01 | Mouse anaesthetization for tMCAO |
TCRb-BV510, clone H57-897 | Biolegend | 109234 | 1:200 dilution |
Zirconia/silica beads, 2.3 mm | Biospec | 11079125z | Beads for tissue homogenization |